This bill directs central government to produce authoritative guidance clarifying how criminal offences apply when healthcare professionals administer pain relief to people who are terminally ill. The aim is to reduce uncertainty that affects clinical decision‑making and the behaviour of police and prosecutors at the bedside.
For clinicians, families and law‑enforcement officials the practical effect would be a single, published reference point about lawful palliative practice at the end of life. That matters because current uncertainty can produce inconsistent prosecutions, risk‑averse clinical practice, and distress for patients and families making end‑of‑life choices.
At a Glance
What It Does
The measure requires the Secretary of State to prepare, consult on, and publish guidance about the criminal law as it relates to healthcare professionals administering pain relief to terminally ill patients. The guidance must address situations that arise shortly before the end of life and may be revised over time.
Who It Affects
The guidance is targeted at chief officers of police and healthcare professionals, but it will also shape decisions by prosecutors, professional regulators and hospital managers. It applies within the territory specified by the bill (see section on extent).
Why It Matters
By producing a common, published account of prosecutorial and policing expectations, the guidance would influence bedside practice, investigation thresholds, and the handling of complaints—without changing statutory offences. For professionals, the guidance would be the nearest thing to an authoritative statement on criminal exposure in end‑of‑life care.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a statutory duty on central government to produce a single, published statement explaining how the criminal law should be applied when clinicians administer pain relief to patients with terminal illnesses. That statement is intended both for police leaders and for clinicians: police to know when to open investigations and how to treat palliative care scenarios; clinicians so they can make treatment choices without an unnecessary fear of criminal liability.
The drafting emphasises cases that occur shortly before death, signalling that the guidance should confront grey‑area situations where a high dose of analgesia may hasten death even if the primary intention is symptom control. The bill does not alter criminal offences or prosecutorial policy by itself; instead it seeks to guide how those existing rules are to be understood and applied in end‑of‑life contexts.The Secretary of State must consult a defined list of stakeholders during preparation, and the finished guidance is to be published and may be revised.
Those procedural requirements create an expectation that the guidance will reflect a mix of clinical best practice, prosecutorial input, and patient/family perspectives, rather than being merely internal government advice.Because the measure is confined to the geographic area specified in the statute, it will not directly change practice in jurisdictions outside that area; nor does it amend healthcare regulation or criminal statutes. Its practical force will depend on uptake by police forces, prosecutors and clinical employers, and on whether professional regulators treat the guidance as relevant to fitness‑to‑practise inquiries.
The Five Things You Need to Know
The Secretary of State must complete and publish the guidance within six months of the Act coming into force.
The guidance must be addressed specifically to chief officers of police and to healthcare professionals.
The Secretary of State must consult terminally ill people and their families, healthcare professionals, the Director of Public Prosecutions, the Attorney General and the Welsh Ministers (and may consult others) while preparing the guidance.
The text requires the guidance to deal in particular with cases where pain relief is administered shortly before the end of life, and it allows the Secretary of State to revise the guidance later.
The Act’s territorial extent is England and Wales, it comes into force on the day it is passed, and it must be published once issued.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Duty to produce guidance and named recipients
This subsection creates the core obligation: the Secretary of State must prepare guidance and direct it to two audiences—chief officers of police and healthcare professionals. Practically, that means the document is intended both to influence policing policy (how investigations should start and be handled) and clinical practice (how clinicians should record, justify and communicate end‑of‑life pain relief). The dual audience shapes tone and content: it must be legally precise enough for police and prosecutors, but clinically informed enough to be usable by bedside practitioners.
Particular focus on treatment shortly before death
The bill singles out administration of pain relief shortly before the end of life for special treatment in the guidance. That directs drafters to confront borderline scenarios—high‑dose analgesia, sedation for refractory symptoms, and timing close to death—where cause and intent can be contested. Expect the guidance to discuss clinical intent, proportionality of doses, record‑keeping, and communication with families as factors that influence whether conduct is pursued under criminal law.
Mandatory consultations and named consultees
The statute prescribes a consultation list: terminally ill people and their families, healthcare professionals, the Director of Public Prosecutions, the Attorney General and the Welsh Ministers, with room to add others. Requiring the DPP and Attorney General positions the guidance to reflect prosecutorial perspectives and legal counsel, rather than being purely clinical. Including patients and families signals a policy aim to factor lived experience into how the law is presented.
Power to revise and duty to publish
The Secretary of State may update the guidance and must arrange for its publication. That combination means the guidance is a living document that can respond to legal developments, case law or clinical advances, and that it will be publicly accessible rather than internal departmental advice. Publication increases the likelihood that courts, regulators and clinicians will cite and rely on the guidance, even though it does not have the force of statute.
Territorial scope, commencement and short title
This short section fixes the Act’s reach—England and Wales only—specifies that the Act comes into force on the day it is passed, and sets the short title. Practically this confines the legal effects of the guidance to those jurisdictions and makes clear that the measure is not a UK‑wide or devolved law change; it also sets an immediate timetable trigger for the six‑month drafting requirement.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Terminally ill patients and their families — clearer published guidance can reduce investigation‑induced distress, improve transparency about what clinicians may lawfully do, and help families understand why certain symptom‑management choices are taken near the end of life.
- Frontline clinicians (doctors, specialist palliative nurses, anaesthetists) — a government guidance document that reflects clinical realities and prosecutorial input can reduce defensive practice and provide a reference for lawful dosing, documentation and communication strategies.
- Directors of Public Prosecutions and police leadership — the guidance offers a nationally endorsed frame for triaging and prosecuting cases, reducing ad hoc decision‑making and the political pressure that can accompany high‑profile end‑of‑life investigations.
- NHS trusts and clinical employers — clearer standards may reduce complaint volumes and litigation risk, and provide a basis for internal protocols and training.
- Legal advisers and in‑house counsel at health providers — a published government text helps frame legal advice to clinicians and managers during difficult end‑of‑life cases.
Who Bears the Cost
- The Secretary of State’s department — drafting, consulting, publishing and periodically revising the guidance will require staff time and possibly external legal and clinical inputs.
- Police forces and the Crown Prosecution Service — forces will need to adapt local investigative practice and train officers; the CPS may need to update charging guidance and train prosecutors on the guidance’s legal interpretations.
- Healthcare providers and NHS trusts — implementing the guidance will require training, revised documentation practices, and potential changes to local policies on symptom control and escalation.
- Professional regulators (e.g., General Medical Council, Nursing & Midwifery Council) — they may face an increase in references to the guidance during fitness‑to‑practise investigations, requiring interpretation against regulatory standards.
- Patients and families in devolved jurisdictions outside the Act’s extent — those stakeholders gain no direct protection under the guidance, which may create uneven outcomes across the UK.
Key Issues
The Core Tension
The central dilemma is between legal clarity and legal constraint: the bill aims to protect clinicians and patients by clarifying when palliative analgesia will not trigger criminal prosecution, but any clarification that lessens perceived legal risk risks being interpreted as easing the boundary with assisted dying or unlawful killing; conversely, a narrowly cautious guidance protects against abuse but perpetuates the very defensive practice and prosecutorial inconsistency the bill seeks to fix.
The bill leaves the criminal law itself untouched while asking government to define its application in end‑of‑life care. That raises two linked implementation challenges.
First, guidance can clarify prosecutorial thresholds and policing priorities but cannot change the underlying criminal offences (murder, manslaughter, assisting suicide). Where the law is contested, courts will remain the ultimate arbiters; guidance can influence but not control prosecutorial decisions or judicial outcomes.
Second, key terms in the bill—most notably “shortly before the end of their life”—are inherently vague. How guidance interprets timing, intent and proportionality will strongly shape practice.
If the guidance is too cautious it will do little to reduce defensive medicine; if it is too permissive it may invite legal challenge or political backlash. Implementation will also depend on the extent to which police forces and prosecutors treat the guidance as binding operationally, and whether professional regulators incorporate it into fitness‑to‑practise assessments.
Resource constraints—time for consultations, training budgets, and CPS capacity—could delay meaningful uptake, and the bill provides no dedicated funding for those activities.
Finally, devolved and cross‑border questions matter in practice. The Act applies to England and Wales and requires consultation with Welsh Ministers, but healthcare delivery and some regulatory levers are devolved.
Clinicians and families in Scotland and Northern Ireland will not be covered, potentially producing inconsistent approaches across the UK. The bill leaves open whether the guidance will engage explicitly with existing legal doctrines (for example the doctrine of double effect) or set out specific clinical examples and dosage guidance—choices that determine how useful the guidance will be at the bedside.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.